Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the read-only/idempotent annotations, the description details data sources (SEC EDGAR/XBRL for company, FAERS/FDA for drug), fiscal-year handling, sorting by primary metric, and output format (paired data + citation URIs). This adds rich behavioral context without contradicting annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense yet efficient, front-loading trigger phrases and the core value proposition. Every sentence serves a purpose: usage examples, preference directive, per-type behavior, sorting, and output formatting. No filler.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given there is no output schema, the description adequately covers return values ('paired data + citation URIs'), sorting, and data sources. It fully addresses the tool's complexity and use cases, leaving no critical gaps for an agent to infer.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

While the schema already describes both parameters, the description enriches them substantially: it explains the 'type' choices (company pulls 10-K financials, drug pulls adverse-event counts) and gives concrete examples for 'values' (tickers vs drug names). This is a meaningful addition beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states a specific action: side-by-side comparison of 2-5 companies or drugs in one call. It distinguishes itself from sequential single-pack lookups, aligning with the sibling entity_profile while explicitly positioning its own role.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Provides explicit trigger phrases ('Compare X and Y', 'X vs Y') and a strong directive: 'ALWAYS PREFER over sequential single-pack lookups when comparing entities.' It also explains when to use type=company vs type=drug, giving clear usage context.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

C2.9/5.0
Disambiguation2/5

The tools fall into two unrelated domains (Ticketmaster event discovery and Pipeworx data research), and within the Pipeworx set there are near-duplicate tools like ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded, plus multiple overlapping prediction-market tools (polymarket_edges, polymarket_arbitrage, polymarket_fill_risk, etc.). An agent would struggle to choose among these overlapping options and may not realize that most tools are unrelated to the server's stated name.

Naming Consistency3/5

Naming uses consistent snake_case, but the pattern is mixed: Ticketmaster resource fetchers are bare nouns (event, venue, attraction, classification) while search tools use verb_noun (event_search, venue_search). Pipeworx tools vary between verb phrases (ask_pipeworx, validate_claim) and descriptive noun phrases (entity_profile, polymarket_kalshi_spread). This inconsistency makes predicting tool names harder, though each name is still readable.

Tool Count2/5

41 tools is excessive for a server titled 'Ticketmaster' when only about 10 are Ticketmaster-related; the other 30 cover an entirely different service (Pipeworx). The count is far beyond a focused scope and suggests the server should be split into two separate, well-scoped MCP servers.

Completeness4/5

For the Ticketmaster half, the surface is complete for read-only event discovery (search events/venues/attractions, get single resources, classifications, autocomplete). For the Pipeworx half, the tool suite is extensive, covering lookup, research, prediction markets, memory, subscriptions, and feedback. The only notable gap is the lack of any write operations, but this is consistent with the read-only nature of the underlying APIs.